LXRX (Lexicon Pharmaceuticals, Inc.) Stock Analysis - Analyst Ratings

Lexicon Pharmaceuticals, Inc. (LXRX) is a publicly traded Healthcare sector company. As of May 21, 2026, LXRX trades at $2.22 with a market cap of $950.58M and a P/E ratio of -31.07. LXRX moved +4.23% today. Year to date, LXRX is +93.86%; over the trailing twelve months it is +287.72%. Its 52-week range spans $0.28 to $2.53. Analyst consensus is strong buy with an average price target of $4.03. Rallies surfaces LXRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate LXRX?

4 analysts cover LXRX: 0 strong buy, 3 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $4.03.

LXRX Key Metrics

Key financial metrics for LXRX
MetricValue
Price$2.22
Market Cap$950.58M
P/E Ratio-31.07
EPS$-0.07
Dividend Yield0.00%
52-Week High$2.53
52-Week Low$0.28
Volume0
Avg Volume0
Revenue (TTM)$69.64M
Net Income$-26.09M
Gross Margin99.50%

LXRX Analyst Consensus

4 analysts cover LXRX: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.03.

Latest LXRX News

Recent LXRX Insider Trades

  • DEBBANE RAYMOND bought 2.00K (~$2.98K) on Feb 25, 2026.
  • DEBBANE RAYMOND bought 100.00K (~$147.00K) on Feb 23, 2026.
  • DEBBANE RAYMOND bought 100.00K (~$147.79K) on Feb 20, 2026.

Common questions about LXRX

What do analysts rate LXRX?
4 analysts cover LXRX: 0 strong buy, 3 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $4.03.
Does Rallies show LXRX price targets?
Yes. Rallies tracks LXRX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is LXRX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LXRX. It does not provide personalized investment advice.
LXRX

LXRX